Anson Funds Management LP Takes $826,000 Position in Profound Medical Corp. (NASDAQ:PROF)

Anson Funds Management LP acquired a new position in shares of Profound Medical Corp. (NASDAQ:PROF - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 110,000 shares of the company's stock, valued at approximately $826,000. Anson Funds Management LP owned about 0.37% of Profound Medical at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FIL Ltd increased its position in Profound Medical by 16.9% during the 4th quarter. FIL Ltd now owns 1,795,000 shares of the company's stock worth $13,486,000 after purchasing an additional 260,000 shares in the last quarter. Gagnon Securities LLC boosted its stake in shares of Profound Medical by 12.6% during the 4th quarter. Gagnon Securities LLC now owns 1,652,531 shares of the company's stock worth $12,411,000 after purchasing an additional 185,284 shares during the last quarter. Timelo Investment Management Inc. grew its holdings in shares of Profound Medical by 21.3% during the fourth quarter. Timelo Investment Management Inc. now owns 911,761 shares of the company's stock worth $6,847,000 after buying an additional 159,954 shares in the last quarter. Gagnon Advisors LLC raised its position in shares of Profound Medical by 20.0% in the fourth quarter. Gagnon Advisors LLC now owns 896,671 shares of the company's stock valued at $6,734,000 after buying an additional 149,445 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Profound Medical during the fourth quarter valued at approximately $6,577,000. Hedge funds and other institutional investors own 47.86% of the company's stock.

Profound Medical Trading Up 4.6 %

Profound Medical stock traded up $0.24 during trading on Monday, reaching $5.47. The company had a trading volume of 161,232 shares, compared to its average volume of 59,999. The firm has a market capitalization of $164.39 million, a price-to-earnings ratio of -4.08 and a beta of 0.44. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.16 and a current ratio of 6.12. The stock's 50 day moving average price is $5.75 and its two-hundred day moving average price is $6.80. Profound Medical Corp. has a 12-month low of $3.90 and a 12-month high of $11.42.

Profound Medical (NASDAQ:PROF - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.11. The company had revenue of $4.18 million for the quarter, compared to the consensus estimate of $5.92 million. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%. As a group, equities analysts expect that Profound Medical Corp. will post -1.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital cut their price target on Profound Medical from $17.00 to $11.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.